Drug duo aims to block Cancer's growth signal in Hard-to-Treat tumors

This study is testing whether two drugs, dabrafenib and trametinib, can shrink or stop the growth of advanced cancers that have a specific genetic change called a BRAF V600 mutation. It is for patients with solid tumors, lymphoma, or multiple myeloma that have not responded to other treatments, but it excludes common cancers like melanoma, lung, and colon cancer. The goal is to see if blocking two key proteins that help cancer cells grow is an effective treatment for these specific cancers.